COMPASS Pathways (CMPS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CMPS COMPASS Pathways

Watchlist

3.490
+0.080+2.35%

Close Jan 17 16:00 ET

3.610
+0.120+3.44%

Post 20:01 ET

322.56MMarket Cap-1.60P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

RBC Capital Reiterates Outperform on Compass Pathways, Maintains $18 Price Target
BenzingaJan 15 09:44 ET · Ratings
Compass Pathways Analyst Ratings
BenzingaJan 15 09:42 ET · Ratings
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $18
Moomoo NewsJan 15 07:31 ET · Ratings
Psychedelic Drug Developer Lykos Could Get Lifeline From Former Tesla Board Member
Seeking AlphaJan 10 13:27 ET
Compass Pathways Prices Offering of American Depositary Shares, Pre-Funded Warrants
MT NewswiresJan 10 09:20 ET
COMPASS Pathways Boosts Funds for Mental Health Trials
TipRanksJan 10 07:33 ET

Comments

Stock_Drift

Dec 18, 2024 05:51

$COMPASS Pathways (CMPS.US)$

IDKWTFIMDOING

Jul 22, 2024 04:21

$COMPASS Pathways (CMPS.US)$
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs

Jaguar8

May 8, 2024 05:31

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Jaguar8

May 2, 2024 06:00

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Moomoo AI

Jan 3, 2024 10:34

Cody Shandraw of Ambria Capital suggests FDA approval for MDMA legalization could be imminent, asserting that MDMA therapy might follow a similar trajectory to JNJ's Spravato treatment for depression. He is thrilled about the potential coverage of the therapy by the U.S. Department of Veterans Affairs for military personnel.

Why One Backer of MDMA Therapy Sees 'Exponential' Growth Following FDA Approval This Year

Heat List

Overall

No Data